DOCSLIB.ORG

Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity Author Manuscript Published OnlineFirst on July 18, 2019; DOI: 10.1158/1078-0432.CCR-19-0832 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and 2 Gilteritinib in Preclinical Models of FLT3-mutated Acute Myeloid Leukemia 3 4 Jun Ma1, Shoujing Zhao1, Xinan Qiao1, Tristan Knight2,3, Holly Edwards4,5, Lisa Polin4,5, 5 Juiwanna Kushner4,5, Sijana H. Dzinic4,5, Kathryn White4,5, Guan Wang1, Lijing Zhao6, Hai Lin7, 6 Yue Wang8, Jeffrey W. Taub2,3, and Yubin Ge3,4,5* 7 8 1National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, 9 Changchun, China 10 2Division of Pediatric Hematology and Oncology, Department of Pediatrics, Children's Hospital 11 of Michigan, Detroit, Michigan, USA 12 3Department of Pediatrics, Wayne State University School of Medicine, Detroit, Michigan, USA 13 4Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan, USA 14 5Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of 15 Medicine, Detroit, Michigan, USA 16 6Department of Rehabilitation, School of Nursing, Jilin University, Changchun, P.R.China 17 7Department of Hematology and Oncology, The First Hospital of Jilin University, Changchun, 18 P.R. China 19 8Department of Pediatric Hematology and Oncology, The First Hospital of Jilin University, 20 Changchun, P.R. China 21 22 *Corresponding author 23 24 Running title: Joint FLT3 and BCL-2 Inhibition in FLT3-mutated AML 25 Keywords: acute myeloid leukemia; FLT3; venetoclax 26 27 GRANT SUPPORT 28 This study was supported by Jilin University, Changchun, China, the Barbara Ann 29 Karmanos Cancer Institute, Wayne State University School of Medicine, and by grants from the 30 National Natural Science Foundation of China, NSFC 31671438 and NSFC 31471295, Graduate 31 Innovation Fund of Jilin University, Hyundai Hope on Wheels, LaFontaine Family/U Can-Cer 32 Vive Foundation, Kids Without Cancer, Children’s Hospital of Michigan Foundation, 33 Decerchio/Guisewite Family, Justin’s Gift, Elana Fund, Ginopolis/Karmanos Endowment and 34 the Ring Screw Textron Endowed Chair for Pediatric Cancer Research. The Animal Model and 35 Therapeutics Evaluation Core and Genomics Core are supported, in part, by NIH Center Grant 36 P30 CA022453 to the Karmanos Cancer Institute at Wayne State University. The funders had no 37 role in study design, data collection, analysis and interpretation of data, decision to publish, or 38 preparation of the manuscript. 39 40 Correspondence: 41 Yubin Ge, PhD 42 Department of Oncology 43 Wayne State University School of Medicine 44 421 East Canfield 45 Detroit, MI, 48201 46 Email: [email protected] 1 Downloaded from clincancerres.aacrjournals.org on September 24, 2021. © 2019 American Association for Cancer Research. Author Manuscript Published OnlineFirst on July 18, 2019; DOI: 10.1158/1078-0432.CCR-19-0832 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 47 Tel: 313 578-4285 48 49 Conflict of interest disclosure: The authors declare no potential conflicts of interest. 50 Abstract word count: 249 51 Manuscript Word Count: 4,158 52 Figures: 6 53 Tables: 0 54 References: 35 55 2 Downloaded from clincancerres.aacrjournals.org on September 24, 2021. © 2019 American Association for Cancer Research. Author Manuscript Published OnlineFirst on July 18, 2019; DOI: 10.1158/1078-0432.CCR-19-0832 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 56 TRANSLATIONAL RELEVANCE 57 Approximately 25% of patients with acute myeloid leukemia (AML) have FLT3-internal tandem 58 duplication (ITD) mutations, which results in constitutive activation of multiple survival 59 pathways. FLT3 inhibitors midostaurin and gilteritinib were recently approved by the US FDA 60 for use in FLT3-mutated AML patients. However, efficacious but short-lived responses with 61 regard to monotherapy and the extensive toxicities and severe side effects of standard induction 62 therapy, demonstrate the need to develop new combination therapies. Here, we show that 63 midostaurin and gilteritinib enhance cell death induced by venetoclax in FLT3-ITD AML cell 64 lines and primary patient samples. Downregulation of Mcl-1 and p-ERK by these inhibitors 65 enhance the antileukemic activity of venetoclax. The combination of gilteritinib and venetoclax 66 shows promising in vivo efficacy in a FLT3-ITD AML cell line-derived xenograft mouse model. 67 These findings support the clinical development of venetoclax in combination with the FLT3 68 inhibitors midostaurin or gilteritinib for the treatment of AML. 69 3 Downloaded from clincancerres.aacrjournals.org on September 24, 2021. © 2019 American Association for Cancer Research. Author Manuscript Published OnlineFirst on July 18, 2019; DOI: 10.1158/1078-0432.CCR-19-0832 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 70 ABSTRACT 71 Purpose: To investigate the efficacy of the combination of the FLT3 inhibitors midostaurin or 72 gilteritinib with the Bcl-2 inhibitor venetoclax in FLT3-ITD acute myeloid leukemia (AML) and 73 the underlying molecular mechanism. 74 Experimental Design: Using both FLT3-ITD cell lines and primary patient samples, annexin V- 75 FITC/propidium iodide staining and flow cytometry analysis were used to quantify cell death 76 induced by midostaurin or gilteritinib, alone or in combination with venetoclax. Western blot 77 analysis was performed to assess changes in protein expression levels of members of the 78 JAK/STAT, MAPK/ERK, and PI3K/AKT pathways, and members of the Bcl-2 family of 79 proteins. The MV4-11-derived xenograft mouse model was used to assess in vivo efficacy of the 80 combination of gilteritinib and venetoclax. Lentiviral overexpression of Mcl-1 was used to 81 confirm its role in cell death induced by midostaurin or gilteritinib with venetoclax. Changes of 82 Mcl-1 transcript levels were assessed by real-time RT-PCR. 83 Results: The combination of midostaurin or gilteritinib with venetoclax potently and 84 synergistically induces apoptosis in FLT3-ITD AML cell lines and primary patient samples. The 85 FLT3 inhibitors induced downregulation of Mcl-1, enhancing venetoclax activity. 86 Phosphorylated-ERK expression is induced by venetoclax but abolished by the combination of 87 venetoclax with midostaurin or gilteritinib. Simultaneous downregulation of Mcl-1 by 88 midostaurin or gilteritinib and inhibition of Bcl-2 by venetoclax results in “free” Bim, leading to 89 synergistic induction of apoptosis. In vivo results show that gilteritinib in combination with 90 venetoclax has therapeutic potential. 91 Conclusion: Inhibition of Bcl-2 via venetoclax synergistically enhances the efficacy of 92 midostaurin and gilteritinib in FLT3-mutated AML. 4 Downloaded from clincancerres.aacrjournals.org on September 24, 2021. © 2019 American Association for Cancer Research. Author Manuscript Published OnlineFirst on July 18, 2019; DOI: 10.1158/1078-0432.CCR-19-0832 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 93 INTRODUCTION 94 Acute myeloid leukemia (AML) is defined by the clonal proliferation of immature 95 myeloid elements and survival rates have remained low in both pediatric and adult patients, with 96 5-year survival rates approximating 61.5-65.1% and 25%, respectively (1). FMS-like tyrosine 97 kinase 3 (FLT3) is a receptor tyrosine kinase and important early regulator of hematopoiesis, in 98 which mutations are seen in approximately one third of AML patients (2). FLT3-internal tandem 99 duplications (ITD) mutations, seen in approximately 25% of patients with AML, result in 100 constitutive activation of downstream pathways which promote cell survival and proliferation, 101 including the MAPK/ERK, PI3K/AKT, and JAK/STAT pathways; understandably, it confers a 102 poor prognosis (2, 3). 103 Direct inhibition of FLT3 is therefore a promising therapeutic avenue, with some agents 104 already available for immediate use. Midostaurin, a first generation multi-kinase inhibitor was 105 approved by the US Food and Drug Administration (FDA) in April 2017 for use in newly 106 diagnosed FLT3-mutated AML patients, in combination with standard 7+3 cytarabine and 107 daunorubicin induction and cytarabine consolidation, on the basis of results of the RATIFY trial 108 (4). In patients over the age of 60 however (e.g. the largest population of AML patients), and 109 those with other comorbidities, 7+3 chemotherapy is not well tolerated due to its extensive 110 toxicities and severe side effects (5). Gilteritinib was approved by the US FDA in November 111 2018 for use in adult patients with relapsed or refractory FLT3-mutated AML, following the 112 ADMIRAL trial (NCT02421939) (6). As such, treatment options for FLT3-mutated AML are 113 beginning to exist, but carry with them certain limitations – particularly in relation to 114 monotherapy, with efficacious but short-lived responses. As such, new therapies to combine with 115 FLT3 inhibitors are an unmet clinical need. 5 Downloaded from clincancerres.aacrjournals.org on September 24, 2021. © 2019 American Association for Cancer Research. Author Manuscript Published OnlineFirst on July 18, 2019; DOI: 10.1158/1078-0432.CCR-19-0832 Author manuscripts have been peer reviewed and accepted for publication
Load more

Recommended publications
  • FLT3 Inhibitors in Acute Myeloid Leukemia Mei Wu1, Chuntuan Li2 and Xiongpeng Zhu2*
    Wu et al. Journal of Hematology & Oncology (2018) 11:133 https://doi.org/10.1186/s13045-018-0675-4 REVIEW Open Access FLT3 inhibitors in acute myeloid leukemia Mei Wu1, Chuntuan Li2 and Xiongpeng Zhu2* Abstract FLT3 mutations are one of the most common findings in acute myeloid leukemia (AML). FLT3 inhibitors have been in active clinical development. Midostaurin as the first-in-class FLT3 inhibitor has been approved for treatment of patients with FLT3-mutated AML. In this review, we summarized the preclinical and clinical studies on new FLT3 inhibitors, including sorafenib, lestaurtinib, sunitinib, tandutinib, quizartinib, midostaurin, gilteritinib, crenolanib, cabozantinib, Sel24-B489, G-749, AMG 925, TTT-3002, and FF-10101. New generation FLT3 inhibitors and combination therapies may overcome resistance to first-generation agents. Keywords: FMS-like tyrosine kinase 3 inhibitors, Acute myeloid leukemia, Midostaurin, FLT3 Introduction RAS, MEK, and PI3K/AKT pathways [10], and ultim- Acute myeloid leukemia (AML) remains a highly resist- ately causes suppression of apoptosis and differentiation ant disease to conventional chemotherapy, with a me- of leukemic cells, including dysregulation of leukemic dian survival of only 4 months for relapsed and/or cell proliferation [11]. refractory disease [1]. Molecular profiling by PCR and Multiple FLT3 inhibitors are in clinical trials for treat- next-generation sequencing has revealed a variety of re- ing patients with FLT3/ITD-mutated AML. In this re- current gene mutations [2–4]. New agents are rapidly view, we summarized the preclinical and clinical studies emerging as targeted therapy for high-risk AML [5, 6]. on new FLT3 inhibitors, including sorafenib, lestaurtinib, In 1996, FMS-like tyrosine kinase 3/internal tandem du- sunitinib, tandutinib, quizartinib, midostaurin, gilteriti- plication (FLT3/ITD) was first recognized as a frequently nib, crenolanib, cabozantinib, Sel24-B489, G-749, AMG mutated gene in AML [7].
    [Show full text]
  • Federal Register Notice 5-1-2020 Pdf Icon[PDF – 358
    Federal Register / Vol. 85, No. 85 / Friday, May 1, 2020 / Notices 25439 confidential by the respondent (5 U.S.C. schedules. Other than examination DEPARTMENT OF HEALTH AND 552(b)(4)). reports, it provides the only financial HUMAN SERVICES Current actions: The Board has data available for these corporations. temporarily revised the instructions to The Federal Reserve is solely Centers for Disease Control and the FR Y–9C report to accurately reflect responsible for authorizing, supervising, Prevention the revised definition of ‘‘savings and assigning ratings to Edges. The [CDC–2020–0046; NIOSH–233–C] deposits’’ in accordance with the Federal Reserve uses the data collected amendments to Regulation D in the on the FR 2886b to identify present and Hazardous Drugs: Draft NIOSH List of interim final rule published on April 28, potential problems and monitor and Hazardous Drugs in Healthcare 2020 (85 FR 23445). Specifically, the develop a better understanding of Settings, 2020; Procedures; and Risk Board has temporarily revised the activities within the industry. Management Information instructions on the FR Y–9C, Schedule HC–E, items 1(b), 1(c), 2(c) and glossary Legal authorization and AGENCY: Centers for Disease Control and content to remove the transfer or confidentiality: Sections 25 and 25A of Prevention, HHS. withdrawal limit. As a result of the the Federal Reserve Act authorize the ACTION: Notice and request for comment. revision, if a depository institution Federal Reserve to collect the FR 2886b chooses to suspend enforcement of the (12 U.S.C. 602, 625). The obligation to SUMMARY: The National Institute for six transfer limit on a ‘‘savings deposit,’’ report this information is mandatory.
    [Show full text]
  • Efficacy and Safety of Midostaurin-Based Induction and Maintenance Therapy for Newly Diagnosed AML
    POST-ASH Issue 4, 2016 Efficacy and Safety of Midostaurin-Based Induction and Maintenance Therapy for Newly Diagnosed AML For more visit ResearchToPractice.com/5MJCASH2016 CME INFORMATION OVERVIEW OF ACTIVITY Each year, thousands of clinicians, basic scientists and other industry professionals sojourn to major international oncology conferences, like the American Society of Hematology (ASH) annual meeting, to hone their skills, network with colleagues and learn about recent advances altering state-of-the-art management in hematologic oncology. These events have become global stages where exciting science, cutting-edge concepts and practice-changing data emerge on a truly grand scale. This massive outpouring of information has enormous benefits for the hematologic oncology community, but the truth is it also creates a major challenge for practicing oncologists and hematologists. Although original data are consistently being presented and published, the flood of information unveiled during a major academic conference is unmatched and leaves in its wake an enormous volume of new knowledge that practicing oncologists must try to sift through, evaluate and consider applying. Unfortunately and quite commonly, time constraints and an inability to access these data sets leave many oncologists struggling to ensure that they’re aware of crucial practice-altering findings. This creates an almost insurmountable obstacle for clinicians in community practice because they are not only confronted almost overnight with thousands of new presentations and
    [Show full text]
  • Disruption of CSF-1R Signaling Inhibits Growth of AML with Inv(16)
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2021 Disruption of CSF-1R signaling inhibits growth of AML with inv(16) Simonis, Alexander ; Russkamp, Norman F ; Mueller, Jan ; Wilk, C Matthias ; Wildschut, Mattheus H E ; Myburgh, Renier ; Wildner-Verhey van Wijk, Nicole ; Mueller, Rouven ; Balabanov, Stefan ; Valk, Peter J M ; Theocharides, Alexandre P A ; Manz, Markus G DOI: https://doi.org/10.1182/bloodadvances.2020003125 Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-202789 Journal Article Published Version The following work is licensed under a Publisher License. Originally published at: Simonis, Alexander; Russkamp, Norman F; Mueller, Jan; Wilk, C Matthias; Wildschut, Mattheus H E; Myburgh, Renier; Wildner-Verhey van Wijk, Nicole; Mueller, Rouven; Balabanov, Stefan; Valk, Peter J M; Theocharides, Alexandre P A; Manz, Markus G (2021). Disruption of CSF-1R signaling inhibits growth of AML with inv(16). Blood advances, 5(5):1273-1277. DOI: https://doi.org/10.1182/bloodadvances.2020003125 STIMULUS REPORT Disruption of CSF-1R signaling inhibits growth of AML with inv(16) Alexander Simonis,1,* Norman F. Russkamp,1,* Jan Mueller,1 C. Matthias Wilk,1 Mattheus H. E. Wildschut,1,2 Renier Myburgh,1 Nicole Wildner-Verhey van Wijk,1 Rouven Mueller,1 Stefan Balabanov,1 Peter J. M. Valk,3 Alexandre P. A. Theocharides,1 and Markus G. Manz1 1Department of Medical Oncology and Hematology, University Hospital
    [Show full text]
  • Recommendations from York and Scarborough Medicines
    Recommendations from York and Scarborough Medicines Commissioning Committee July 2018 Drug name Indication Recommendation, rationale and place in RAG status Potential full year cost impact therapy CCG commissioned Technology Appraisals 1. Nil NHSE commissioned Technology Appraisals – for noting 2. TA520: Atezolizumab for Atezolizumab is recommended as an option for Red No cost impact to CCGs as NHS England treating locally advanced or treating locally advanced or metastatic non- commissioned. metastatic non-small-cell lung small-cell lung cancer (NSCLC) in adults who cancer after chemotherapy have had chemotherapy (and targeted treatment if they have an EGFR- or ALK‑ positive tumour), only if: atezolizumab is stopped at 2 years of uninterrupted treatment or earlier if the disease progresses and the company provides atezolizumab with the discount agreed in the patient access scheme. 3. TA522: Pembrolizumab for Pembrolizumab is recommended for use within Red No cost impact to CCGs as NHS England untreated locally advanced or the Cancer Drugs Fund as an option for commissioned. metastatic urothelial cancer untreated locally advanced or metastatic when cisplatin is unsuitable urothelial carcinoma in adults when cisplatin- containing chemotherapy is unsuitable, only if: pembrolizumab is stopped at 2 years of uninterrupted treatment or earlier if the disease progresses and the conditions of the managed access agreement for pembrolizumab are followed TA523: Midostaurin for Midostaurin is recommended, within its Red No cost impact to CCGs as NHS England untreated acute myeloid marketing authorisation, as an option in adults commissioned. leukaemia for treating newly diagnosed acute FLT3- mutation-positive myeloid leukaemia with standard daunorubicin and cytarabine as induction therapy, with high-dose cytarabine as consolidation therapy, and alone after complete response as maintenance therapy.
    [Show full text]
  • Samaritan Fund
    Items supported by the Samaritan Fund (a) Non-drug Items supported by the Fund (b) Other items supported by the Samaritan Fund Mechanism (c) Self-financed Drugs supported by the Samaritan Fund (SF) and Community Care Fund (CCF) Medical Assistance Programme (First Phase Programme) (for specified self- financed cancer drugs) (a) Non-drug Items supported by the Fund 1. Percutaneous Transluminal Coronary Angioplasty (PTCA) and other consumables for interventional cardiology 2. Cardiac Pacemakers 3. Myoelectric Prosthesis 4. Custom-made Prosthesis 5. Appliances for prosthetic and orthotic services, physiotherapy and occupational therapy services (e.g. prosthesis) 6. Home use equipment and appliances (e.g. wheelchair, replacement of external speech processor for patients done with cochlear implant) 7. Gamma knife surgery 8. Harvesting of marrow in a foreign country for marrow transplant The Fund will only support the model which can meet the basic medical needs of the patients. (b) Other items supported by the Samaritan Fund Mechanism 1. Positron Emission Tomography (PET) service (c) Drugs supported by the Samaritan Fund The following specific self-financed drugs are supported by the Samaritan Fund: Item Drug Types of Clinical indications diseases 1 Abatacept Rheumatology Rheumatoid arthritis 2a Adalimumab Dermatology Severe psoriasis 2b Ophthalmology Non-infectious intermediate, posterior and panuveitis 2c Paediatric chronic non-infectious anterior uveitis 2d Rheumatology Ankylosing spondylitis 2e Juvenile idiopathic arthritis 2f Psoriatic
    [Show full text]
  • PRAC Draft Agenda of Meeting 11-14 May 2020
    11 May 2020 EMA/PRAC/257460/2020 Human Division Pharmacovigilance Risk Assessment Committee (PRAC) Draft agenda for the meeting on 11-14 May 2020 Chair: Sabine Straus – Vice-Chair: Martin Huber 11 May 2020, 10:30 – 19:30, via teleconference 12 May 2020, 08:30 – 19:30, via teleconference 13 May 2020, 08:30 – 19:30, via teleconference 14 May 2020, 08:30 – 16:00, via teleconference Organisational, regulatory and methodological matters (ORGAM) 28 May 2020, 09:00-12:00, via teleconference Disclaimers Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also change during the course of the review. Additional details on some of these procedures will be published in the PRAC meeting highlights once the procedures are finalised. Of note, this agenda is a working document primarily designed for PRAC members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006, Rev. 1). Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020.
    [Show full text]
  • Self-Administered Specialty Drug List
    Self‐Administered Drug List BRAND NAME GENERIC DRUG NME ABIRATERONE ACETATE ABIRATERONE ACETATE ACTEMRA TOCILIZUMAB ACTEMRA ACTPEN TOCILIZUMAB ACTHAR CORTICOTROPIN ACTIMMUNE INTERFERON GAMMA‐1B,RECOMB ADCIRCA TADALAFIL ADEMPAS RIOCIGUAT AFINITOR EVEROLIMUS AFINITOR DISPERZ EVEROLIMUS ALECENSA ALECTINIB HCL ALUNBRIG BRIGATINIB ALYQ TADALAFIL AMBRISENTAN AMBRISENTAN AMPYRA DALFAMPRIDINE APOKYN APOMORPHINE HCL ARANESP DARBEPOETIN ALFA IN POLYSORBAT ARCALYST RILONACEPT ARIKAYCE AMIKACIN LIPOSOMAL/NEB.ACCESSR ARIXTRA FONDAPARINUX SODIUM AUBAGIO TERIFLUNOMIDE AUSTEDO DEUTETRABENAZINE AVEED TESTOSTERONE UNDECANOATE AVONEX INTERFERON BETA‐1A AVONEX INTERFERON BETA‐1A/ALBUMIN AVONEX PEN INTERFERON BETA‐1A AYVAKIT AVAPRITINIB BAFIERTAM MONOMETHYL FUMARATE BALVERSA ERDAFITINIB BENLYSTA BELIMUMAB BETASERON INTERFERON BETA‐1B BETHKIS TOBRAMYCIN BOSENTAN BOSENTAN BOSULIF BOSUTINIB BRAFTOVI ENCORAFENIB BRONCHITOL MANNITOL BRUKINSA ZANUBRUTINIB BYNFEZIA OCTREOTIDE ACETATE CABENUVA CABOTEGRAVIR/RILPIVIRINE CABLIVI CAPLACIZUMAB‐YHDP CABOMETYX CABOZANTINIB S‐MALATE CALQUENCE ACALABRUTINIB CAPECITABINE CAPECITABINE CAPRELSA VANDETANIB CARBAGLU CARGLUMIC ACID CAYSTON AZTREONAM LYSINE CERDELGA ELIGLUSTAT TARTRATE CETROTIDE CETRORELIX ACETATE CHENODAL CHENODIOL CHOLBAM CHOLIC ACID CHORIONIC GONADOTROPIN CHORIONIC GONADOTROPIN, HUMAN CIMZIA CERTOLIZUMAB PEGOL COPAXONE GLATIRAMER ACETATE COPIKTRA DUVELISIB COSENTYX (2 SYRINGES) SECUKINUMAB COSENTYX PEN SECUKINUMAB COSENTYX PEN (2 PENS) SECUKINUMAB COSENTYX SYRINGE SECUKINUMAB COTELLIC COBIMETINIB FUMARATE CYSTADANE
    [Show full text]
  • NEW 2018 Specialty Drugs
    Specialty Medications by Disease Type updated 7/2/18 ALLERGY AND ASTHMA Brand Name Generic FASENRA BENRALIZUMAB NUCALA MEPOLIZUMAB XOLAIR OMALIZUMAB CYSTIC FIBROSIS Brand name Generic BETHKIS TOBRAMYCIN CAYSTON AZTREONAM CREON PANCRELIPASE HYPERSAL SODIUM CHLORIDE 7% (HYPERTONIC SALINE) KALYDECO IVACAFTOR ORKAMBI LUMACAFTOR/IVACAFTOR PANCREAZE PANCRELIPASE PERTZYE PANCRELIPASE PULMOZYME DORNASE ALFA SYMDEKO TEZACAFTOR/IVACAFTOR TOBI/ TOBI PODHALER TOBRAMYCIN ULTRESA PANCRELIPASE VIOKASE PANCRELIPASE ZENPEP PANCRELIPASE DERMATOLOGY Brand name Generic COSENTYX SECUKINUMAB DUPIXENT DUPILUMAB ENBREL ETANERCEPT HUMIRA ADALIMUMAB OTEZLA APREMILAST OTREXUP METHOTREXATE RASUVO METHOTREXATE STELARA USTEKINUMAB TALTZ IXEKIZUMAB TREMFYA GUSELKUMAB XOLAIR OMALIZUMAB ENDOCRINE DISORDERS AVEED TESTOSTERONE UNDECANOATE LUPRON LEUPROLIDE MAKENA HYDROXYPROGESTERONE CAPROATE SOMATULINE LANREOTIDE SANDOSTATIN OCTREOTIDE SUPPRELIN HISTRELIN VANTAS HISTRELIN GROWTH HORMONE DEFICIENCY Brand name Generic GENOTROPIN SOMATROPIN HUMATROPE SOMATROPIN NORDITROPIN SOMATROPIN NUTROPIN SOMATROPIN OMNITROPE SOMATROPIN SAIZEN SOMATROPIN SEROSTIM SOMATROPIN ZOMACTON SOMATROPIN ZORBTIVE SOMATROPIN HEPATITIS Brand name Generic BARACLUDE ENTECAVIR DAKLINZA DACLATASVIR EPCLUSA SOFOSBUVIR/VELPATASVIR HARVONI LEDIPASVIR/SOFOSBUVIR MAVYRET GLECAPREVIR/PIBRENTASVIR OLYSIO SIMEPREVIR PEGASYS PEGINTERFERON ALFA-2A PEGINTRON PEGINTERFERON ALFA-2B RIBAVIRIN SOVALDI SOFOSBUVIR TECHNIVIE OMBITASVIR/PARITAPREVIR/RITONAVIR VIEKIRA OMBITASVIR/PARITAPREVIR/RITONAVIR/DASABUVIR VEMLIDY TENOFOVIR
    [Show full text]
  • Simulating Protein–Ligand Binding with Neural Network Potentials
    Electronic Supplementary Material (ESI) for Chemical Science. This journal is © The Royal Society of Chemistry 2020 Supporting Information: Simulating Protein{Ligand Binding with Neural Network Potentials Shae-Lynn J. Lahey and Christopher N. Rowley∗ Department of Chemistry, Memorial University of Newfoundland, St. John's, NL, Canada E-mail: [email protected] Table S1: Table of crystallographic data. Ligands that did not have a common drug name are listed by their Drugbank ID or their compound ID number(CID). PDB ID Protein EC Ligand Resolution (A)˚ Temp (K) 1XOZS1 phosphodi-esterase 5A 3.1.4.17 tadalafil 1.37 93 3EYGS2 JAK1 2.7.10.2 tofacitinib 1.9 100 2W6NS3 biotin carboxylase 6.3.4.14 DB08315 1.87 100 4HJOS4 EGFR 2.7.10.1 erlotinib 2.21 110 4NCTS5 Human DYRK1A 2.7.12.1 midostaurin 2.6 100 2HYYS6 Abl kinase 2.7.10.2 imatinib 2.4 100 3EIGS7 dihydrofolate reductase 1.5.1.3 methotrexate 1.7 93 3ETAS8 IGF-1R 2.7.10.1 CID 45272927 2.6 93 S-1 Table S2: Table of RMSD of the calculated structures of the ligands relative to the PDB structure. RMSD (A)˚ PDB ID CGenFF NNP/MM 1XOZ 0.19 0.13 3EYG 0.24 0.50 2W6N 0.54 0.57 4HJO 0.79 0.59 4NCT 1.1 0.60 2HYY 0.39 0.42 3EIG 0.37 0.28 3ETA 0.26 0.35 Figure S1: Trajectory of the RMSD of the calculated structure of 4HJO vs the PDB Structure vs time. S-2 NH2 O O N O O O N N N O N O N O N H N N O NH HN N N O N O 1XOZ 2W6N 3EYG 4HJO phosphodiesterase 5A biotin carboxylase JAK1 EGFR tadalafil DB08315 tofacitinib erlotinib O O O H O O N H N H N O HN O N N N O NH2 N O N HN N HN O N N N H2N N N O O HN N NH+ + N NH3 4NCT 2HYY 3EIG 3ETA human DYRK1A Abl kinase dihydrofolate reductase insulin receptor kinase midostaurin imatinib methotrexate Pubchem: 25920884 Figure S2: Calculated poses of ligands.CGenFF is in green and ANI is in red.
    [Show full text]
  • (CAR)-Modified Immune Effector Cell Therapy for Acute Myeloid Leukemia
    cancers Review Chimeric Antigen Receptor (CAR)-Modified Immune Effector Cell Therapy for Acute Myeloid Leukemia (AML) Utkarsh H. Acharya 1,2,* and Roland B. Walter 3,4,5,6 1 Divisions of Hematologic Malignancies & Immune Effector Cell Therapy, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA 2 Department of Medicine, Harvard Medical School, Boston, MA 02215, USA 3 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; [email protected] 4 Department of Medicine, Division of Hematology, University of Washington, Seattle, WA 98195, USA 5 Department of Laboratory Medicine & Pathology, University of Washington, Seattle, WA 98195, USA 6 Department of Epidemiology, University of Washington, Seattle, WA 98195, USA * Correspondence: [email protected]; Tel.: +1-857-215-0396 Received: 12 November 2020; Accepted: 1 December 2020; Published: 3 December 2020 Simple Summary: Adoptive cell transfer with chimeric antigen receptor (CAR)-modified immune effector cells (IECs) has quickly emerged as a paradigm-shifting approach for the management of B cell malignancies given its ability to induce high rates of remission. This is reflected by the regulatory approval of three CD19-directed CAR T cell products to date for the treatment of several non-Hodgkin lymphomas and pediatric/young adult B-acute lymphoblastic leukemia (B-ALL). While fueled by this success, the use of CAR-modified IECs in acute myeloid leukemia (AML) is still in its infancy, with recognized challenges involving the selection of suitable target antigens, immune resistance due to a hostile tumor microenvironment, and potentially fatal toxicity to normal cells, in particular hematopoietic cells.
    [Show full text]
  • View of This Manuscript
    Liu Biomarker Research (2019) 7:25 https://doi.org/10.1186/s40364-019-0178-7 EDITORIAL Open Access Cancer biomarkers for targeted therapy Delong Liu1,2 Abstract Tumor-associated antigens (TAA) or cancer biomarkers are major targets for cancer therapies. Antibody- based agents targeting the cancer biomarkers include monoclonal antibodies (MoAbs), radiolabeled MoAbs, bispecific T cell engagers, and antibody-drug conjugates. Antibodies targeting CD19, CD20, CD22, CD30, CD33, CD38, CD79B and SLAMF7 are in clinical applications for hematological malignancies. CD123, CLL-1, B cell maturation antigen, and CD138 are targets for cancer immunotherapeutic agents, including the chimeric antigen receptor - engineered T cells. Immune checkpoint inhibitors (ICIs) against PD-1, PD-L1, and CTLA-4 have led to the revolution of cancer immunotherapy. More ICIs targeting IDO, LAG3, TIM-3, TIGIT, SIGLECs, VISTA and CD47 are being explored. Small molecule inhibitors (SMIs) against tyrosine kinase oncoproteins such as BCR-ABL, JAK2, Bruton tyrosine kinase, FLT3, EGFR, ALK, HER2, VEGFR, FGFR, MEK, and MET have fundamentally changed the landscape of cancer therapy. SMIs against BCL-2, IDHs, BRAF, PI3 kinase, mTOR, PARP, and CDKs have become the mainstay in the treatment of a variety of cancer types. To reduce and avoid off-tumor toxicities, cancer-specific TAAs such as CD33 are being manufactured through systems biology approach. Search for novel biomarkers and new designs as well as delivery methods of targeted agents are fueling the next wave of advances in cancer therapy. Keywords: Biomarker, Tumor-associated antigen, BiTE, Antibody-drug conjugate, CAR-T Tumor-associated antigens (TAA) or cancer biomarkers including coltuximab ravtansine (SAR3419), denintuzu- are major targets for cancer therapies.
    [Show full text]